COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer

J Surg Oncol. 2013 Nov;108(6):409-13. doi: 10.1002/jso.23416. Epub 2013 Aug 23.

Abstract

Background and objectives: Despite its dwindling occurrence, gastric cancer remains a leading cause of cancer related mortality worldwide. Molecular determinants of prognosis that impact survival are being sought out as a means to facilitate rational clinical decision-making and enhance patient management. In this study, we evaluated three molecules implicated in gastric carcinogenesis and demonstrated that the differential expression of cyclooxygenase-2 (COX-2) and the viral oncogene homolog Src proteins could explain the differences in survival observed in patients older and younger than 50 years of age.

Methods: We evaluated 5-year survival in a cohort of 423 gastric cancer patients using chronological age as a variable. Additionally, we assessed the protein expression of three molecules (COX-2, TFF1, Src) implicated in the pathogenesis of gastric cancer using immunohistochemistry.

Results: We found that patients younger than 50 years of age had a better 5-year survival rate in all tumor stages. We found that the expression of COX-2 and Src correlated significantly with survival in this group without any significant impact attributable to TFF1.

Conclusions: Our study demonstrates that young gastric cancer patients have a better prognostic outlook that could in part be explained by the differential expression of COX-2 and Src.

Keywords: better survival; gastric cancer; young patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Biomarkers, Tumor / analysis*
  • Carcinoma / chemistry*
  • Carcinoma / mortality*
  • Carcinoma / pathology
  • Carcinoma / surgery
  • Cyclooxygenase 2 / analysis*
  • Esophagogastric Junction
  • Female
  • Germany
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Predictive Value of Tests
  • Prognosis
  • Prospective Studies
  • Proto-Oncogene Proteins pp60(c-src) / analysis*
  • Retrospective Studies
  • Stomach Neoplasms / chemistry*
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Tissue Array Analysis
  • Trefoil Factor-1
  • Tumor Suppressor Proteins / analysis*

Substances

  • Biomarkers, Tumor
  • TFF1 protein, human
  • Trefoil Factor-1
  • Tumor Suppressor Proteins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Proto-Oncogene Proteins pp60(c-src)